Pharmaceutical companies left a Tuesday meeting with Medicare officials with no new answers on how the federal government will negotiate the prices of the highest-spending drugs, according to two industry sources.
The Centers for Medicare & Medicaid Services held its first in a series of monthly calls with drugmakers on implementation of the Inflation Reduction Act’s (Public Law 117-169) drug pricing provisions. The industry sources said CMS officials declined to answer questions on how the CMS will identify drugs eligible for negotiations starting in 2026.
Tuesday’s call, which was restricted to drug manufacturers, comes as industry and policy ...